In summary, this is the first study aimed at evaluating the possible use of PTP4A2 as a clinically relevant indicator for NPC aggressiveness and as a prognostic marker for patient survival in NPC. The gene discussed is PTP4A2; the disease is nasopharyngeal carcinoma.